Ligature Therapeutics (LTx) is an early-stage biotech company generating targeted protein degraders (TPD). LTx is advancing its structure agnostic fragment-based drug discovery platform to generate cancer-selective TPDs, and has achieved early proof of concept with a lead asset.
Ligature Therapeutics was an A*STAR (EDDC) spin-off company founded in 2020 with investment from Lightstone Singapore and SEEDS Capital.
Company Details
- Founded
- -
- Address
- Singapore, Sg
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Singapore
Ligature Therapeutics Questions
Ligature Therapeutics's LinkedIn profile is https://sg.linkedin.com/company/ligaturetx
Ligature Therapeutics's industry is
Biotechnology Research
Ligature Therapeutics's top competitors are
Carmine Therapeutics,
Tessa Therapeutics Ltd,
Trinity Innovation Bioventure Singapore,
Singzyme,
Lerna Biopharma,
Neurovanda Therapeutics,
Biotech Connection Singapore,
Nuevocor,
Axcynsis Therapeutics,
Hummingbird Bioscience.
Ligature Therapeutics's categories are Biotechnology Research
Ligature Therapeutics's founding year is 2020
